‘courtesy of you, the entire Kaiser Daily Health Policy view Report, search the archives, or sign up be published for e-mail notification to Kaiser Daily Health Policy Report strongly supports imperial network. A free service of The Henry J. Kaiser Family Foundation impotens . 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
This press release contains forward-looking statements or projections. Such forward-looking statements include statements regarding the potential for tezampanel and NGX426 to treat them as treatments for migraine and other pain indications and the potential of the Company ‘s product candidates for specific diseases and disorders. Such statements are subject to numerous factors, risks and uncertainties that cause actual events or from from current expectations of of the merged company. Mean TorreyPines Therapeutics drug candidates are subject to risks and uncertainties relating to the development, approval and commercialization, including whether preclinical studies or clinical trials, ongoing or conducted in the future will prove successful, and whether successful, whether the results can be replicated, if the security and efficacy profiles is constructed by one of its drug candidate, or if it is determined to remain the same, better or worse in future clinical trials, if present, whether pre-clinical results of ongoing or will be detected future clinical studies, if any, or if one of its its drug candidates able signs or symptoms signs and symptoms of each clinical indication, whether their drug candidates, an NDA submission to support, SEC reports.roved by the FDA or the equivalent, or if approved, will be competitive on the market, or whether the necessary funding to be their drug development programs support is available. Actual results may differ materially from the above forward-looking statements due to a number of other important factors, including that TorreyPines Therapeutics may not be able to execute to realize its integration strategies and the anticipated benefits of the recently completed merger with Axonyx, These and other risks that may affect the expectations of management, are in more detail described in the Registration Statement on form S-4, as amended, with the Securities and Exchange Commission and the other Axonyx filed SEC reports. TorreyPines Therapeutics assumes no obligation to publicly the result of of any revisions to these forward – looking statements that are made to reflect events or circumstances after the date hereof the occurrence of unanticipated the occurrence of unanticipated events. (more…)